Nxera Pharma Collaborates with Handok to Commercialize Pivlaz in South Korea
Shots:
- Nxera Pharma (formerly Sosei Heptares) has signed an exclusive supply & distribution agreement with Handok for commercializing Pivlaz (clazosentan sodium) 150mg across South Korea
- Under the collaboration, Nxera will supply Pivlaz to Handok at an agreed cost while Handok will exclusively handle its promotion, marketing, sales & distribution. Nxera is entitled to receive a one-off upfront upon signing along with commercial milestones & a share of sales generated from product supply
- Pivlaz is indicated for preventing cerebral vasospasm, vasospasm-related cerebral infarction & cerebral ischemic symptoms post aneurysmal subarachnoid hemorrhage (aSAH) & will be launched across South Korea in 2025
Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim
Related News:- Boehringer Ingelheim and Sosei Heptares Collaborate for the Development of Therapies to Address Schizophrenia Symptoms
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
